Brief: Jemperli (Dostarlimab-Gxly) Approved In Us As First And Only Immunotherapy For Adults With Msi-H/Dmmr Locally Advanced Rectal Cancer
Mon 23:30
BRIEF-Jemperli (Dostarlimab-Gxly) Approved In Us As First And Only Immunotherapy For Adults With Msi-H/Dmmr Locally Advanced Rectal Cancer Oct 19 (Reuters) - GSK plc GSK.L:
JEMPERLI (DOSTARLIMAB-GXLY) APPROVED IN US AS FIRST AND ONLY IMMUNOTHERAPY FOR ADULTS WITH MSI-H/DMMR LOCALLY ADVANCED RECTAL CANCER
Source text: ID:nBw23CM2ra
Further company coverage: GSK.L
((((Reuters.Briefs@thomsonreuters.com;));))